Biodesix Inc
BDSX
View Detailed Chart
10.380USD
+0.420+4.22%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
82.57MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.22%
5 Days
+2.06%
1 Month
+72.14%
6 Months
+33.08%
Year to Date
+52.65%
1 Year
-50.10%
View Detailed Chart
TradingKey Stock Score of Biodesix Inc
Currency: USD Updated: 2026-02-06Key Insights
Biodesix Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biodesix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Biodesix Inc Highlights
StrengthsRisks
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 86.65% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 71.32M.
Fairly Valued
The company’s latest PE is -1.98, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 192.14K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
32.500
Target Price
+226.31%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biodesix Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biodesix Inc Info
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Ticker SymbolBDSX
CompanyBiodesix Inc
CEOHutton (Scott)
Websitehttps://www.biodesix.com/
Related Instruments
+3.02%
+0.09%
+1.60%
+2.48%
+0.40%
-1.14%
-0.05%
-2.35%
-1.76%
+2.65%
+2.64%
+2.03%
+2.01%
+2.38%
+1.70%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68595.320
-1374.810 (-1.97%)
282.580
+22.390 (+8.61%)
2038.240
-13.490 (-0.66%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
